Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection

Inge Derdelinckx; Mark A Wainberg; Joep M. A Lange; Andrew Hill; Yasmin Halima; Charles A. B Boucher

doi:10.1371/journal.pmed.0030454

Loading metrics

Open Access

Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection

Inge Derdelinckx,
Mark A Wainberg,
Joep M. A Lange,
Andrew Hill,
Yasmin Halima,
Charles A. B Boucher

*To whom correspondence should be addressed. E-mail:c.boucher@umcutrecht.nl
⨯

Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection

Inge Derdelinckx,
Mark A Wainberg,
Joep M. A Lange,
Andrew Hill,
Yasmin Halima,
Charles A. B Boucher

Published: November 7, 2006
https://doi.org/10.1371/journal.pmed.0030454

About the Authors

Inge Derdelinckx
Mark A Wainberg
Joep M. A Lange
Andrew Hill
Yasmin Halima
Charles A. B Boucher: *To whom correspondence should be addressed. E-mail:c.boucher@umcutrecht.nl

Competing Interests

ID received travel grants from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Roche. MAW declares that he has no competing interests. JAL declares that he has received honoraria for advice, speaking engagements, or research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche, and Tibotec. AH has received consultancy payments from Tibotec (Johnson and Johnson). YH received a travel grant to participate in a GlaxoSmithKline advisory board. CABB serves or has served on scientific (HIV) advisory boards, spoken at symposia of, and/or received research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Roche. He declares that he does not own any pharmaceutical company stock. He is a grant holder of various European Community grants for the study of HIV drug resistance and drug resistance transmission. He also serves as a member of the World Health Organization HIV ResNet advisory body and is a member of organising committees of several meetings on HIV.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV infections
Is the Subject Area "HIV infections" applicable to this article?

Thanks for your feedback.
HIV prevention
Is the Subject Area "HIV prevention" applicable to this article?

Thanks for your feedback.
HIV epidemiology
Is the Subject Area "HIV epidemiology" applicable to this article?

Thanks for your feedback.
Viral replication
Is the Subject Area "Viral replication" applicable to this article?

Thanks for your feedback.
HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Antivirals
Is the Subject Area "Antivirals" applicable to this article?

Thanks for your feedback.
Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.